BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26731559)

  • 1. MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma.
    Saldanha G; Potter L; Lee YS; Watson S; Shendge P; Pringle JH
    Melanoma Res; 2016 Feb; 26(1):21-8. PubMed ID: 26731559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN.
    Mao XH; Chen M; Wang Y; Cui PG; Liu SB; Xu ZY
    Mol Carcinog; 2017 Mar; 56(3):886-894. PubMed ID: 27533779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
    Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
    J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRF1 and NRF2 mRNA and Protein Expression Decrease Early during Melanoma Carcinogenesis: An Insight into Survival and MicroRNAs.
    Hämäläinen M; Teppo HR; Skarp S; Haapasaari KM; Porvari K; Vuopala K; Kietzmann T; Karihtala P
    Oxid Med Cell Longev; 2019; 2019():2647068. PubMed ID: 31687076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
    Sand M; Skrygan M; Sand D; Georgas D; Gambichler T; Hahn SA; Altmeyer P; Bechara FG
    Cell Tissue Res; 2013 Jan; 351(1):85-98. PubMed ID: 23111773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
    Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
    J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microrna profiling analysis of differences between the melanoma of young adults and older adults.
    Jukic DM; Rao UN; Kelly L; Skaf JS; Drogowski LM; Kirkwood JM; Panelli MC
    J Transl Med; 2010 Mar; 8():27. PubMed ID: 20302635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.
    Bucheit AD; Chen G; Siroy A; Tetzlaff M; Broaddus R; Milton D; Fox P; Bassett R; Hwu P; Gershenwald JE; Lazar AJ; Davies MA
    Clin Cancer Res; 2014 Nov; 20(21):5527-36. PubMed ID: 25165098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seed targeting with tiny anti-miR-1297 inhibits EMT in melanoma cells.
    Han Y; Li X; Ma C; Ji X; Li T; Zheng X; Zhang J; Yan J; Zhang D; Bai J
    J Drug Target; 2019 Jan; 27(1):75-81. PubMed ID: 29873263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
    Tsao H; Goel V; Wu H; Yang G; Haluska FG
    J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The High Expression of the microRNA 17-92 Cluster and its Paralogs, and the Downregulation of the Target Gene PTEN, Is Associated with Primary Cutaneous B-Cell Lymphoma Progression.
    Battistella M; Romero M; Castro-Vega LJ; Gapihan G; Bouhidel F; Bagot M; Feugeas JP; Janin A
    J Invest Dermatol; 2015 Jun; 135(6):1659-1667. PubMed ID: 25634356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
    Forloni M; Dogra SK; Dong Y; Conte D; Ou J; Zhu LJ; Deng A; Mahalingam M; Green MR; Wajapeyee N
    Elife; 2014 Feb; 3():e01460. PubMed ID: 24550252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA-10b is a prognostic biomarker for melanoma.
    Saldanha G; Elshaw S; Sachs P; Alharbi H; Shah P; Jothi A; Pringle JH
    Mod Pathol; 2016 Feb; 29(2):112-21. PubMed ID: 26743475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN.
    Ling JW; Lu PR; Zhang YB; Jiang S; Zhang ZC
    Genet Mol Res; 2017 Aug; 16(3):. PubMed ID: 28829890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells.
    Komina A; Palkina N; Aksenenko M; Tsyrenzhapova S; Ruksha T
    PLoS One; 2016; 11(12):e0168229. PubMed ID: 28005927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN, A Target of Microrna-374b, Contributes to the Radiosensitivity of Canine Oral Melanoma Cells.
    Noguchi S; Ogusu R; Wada Y; Matsuyama S; Mori T
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
    Wandler A; Riber-Hansen R; Hager H; Hamilton-Dutoit SJ; Schmidt H; Nielsen BS; Stougaard M; Steiniche T
    Melanoma Res; 2017 Oct; 27(5):417-428. PubMed ID: 28614272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
    Tsao H; Zhang X; Fowlkes K; Haluska FG
    Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.